Trial Profile
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 10 Apr 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.
- 16 Jul 2019 Planned End Date changed from 1 Oct 2018 to 1 Dec 2019.